Cargando…
Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement
A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings, triple therapy with a serotonin (5-hydroxytr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735961/ https://www.ncbi.nlm.nih.gov/pubmed/29244998 http://dx.doi.org/10.1200/JGO.2016.005728 |
_version_ | 1783287303658012672 |
---|---|
author | Chan, Alexandre Abdullah, Matin M. Ishak, Wan Zamaniah B. Wan Ong-Cornel, Annielyn B. Villalon, Antonio H. Kanesvaran, Ravindran |
author_facet | Chan, Alexandre Abdullah, Matin M. Ishak, Wan Zamaniah B. Wan Ong-Cornel, Annielyn B. Villalon, Antonio H. Kanesvaran, Ravindran |
author_sort | Chan, Alexandre |
collection | PubMed |
description | A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings, triple therapy with a serotonin (5-hydroxytryptamine-3 [5-HT(3)]) antagonist (preferably palonosetron), dexamethasone, and aprepitant is recommended for acute CINV prevention. In resource-restricted settings, triple therapy is still recommended, although a 5-HT(3) antagonist other than palonosetron may be used. In both general and resource-restricted settings, dual therapy with dexamethasone (days 2 to 4) and aprepitant (days 2 to 3) is recommended to prevent delayed CINV. In patients treated with moderately emetogenic chemotherapy, dual therapy with a 5-HT(3) antagonist, preferably palonosetron, and dexamethasone is recommended for acute CINV prevention in general settings; any 5-HT(3) antagonist can be combined with dexamethasone in resource-restricted environments. In general settings, for the prevention of delayed CINV associated with moderately emetogenic chemotherapy, corticosteroid monotherapy on days 2 and 3 is recommended. If aprepitant is used on day 1, it should be continued on days 2 and 3. Prevention of delayed CINV with corticosteroids is preferred in resource-restricted settings. The expert panel also developed CINV management guidelines for anthracycline plus cyclophosphamide combination schedules, multiday cisplatin, and chemotherapy with low or minimal emetogenic potential, and its recommendations are detailed in this review. Overall, these regional guidelines provide definitive guidance for CINV management in general and resource-restricted settings. These consensus recommendations are anticipated to contribute to collaborative efforts to improve CINV management in Southeast Asia. |
format | Online Article Text |
id | pubmed-5735961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-57359612018-01-03 Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement Chan, Alexandre Abdullah, Matin M. Ishak, Wan Zamaniah B. Wan Ong-Cornel, Annielyn B. Villalon, Antonio H. Kanesvaran, Ravindran J Glob Oncol Special Articles A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings, triple therapy with a serotonin (5-hydroxytryptamine-3 [5-HT(3)]) antagonist (preferably palonosetron), dexamethasone, and aprepitant is recommended for acute CINV prevention. In resource-restricted settings, triple therapy is still recommended, although a 5-HT(3) antagonist other than palonosetron may be used. In both general and resource-restricted settings, dual therapy with dexamethasone (days 2 to 4) and aprepitant (days 2 to 3) is recommended to prevent delayed CINV. In patients treated with moderately emetogenic chemotherapy, dual therapy with a 5-HT(3) antagonist, preferably palonosetron, and dexamethasone is recommended for acute CINV prevention in general settings; any 5-HT(3) antagonist can be combined with dexamethasone in resource-restricted environments. In general settings, for the prevention of delayed CINV associated with moderately emetogenic chemotherapy, corticosteroid monotherapy on days 2 and 3 is recommended. If aprepitant is used on day 1, it should be continued on days 2 and 3. Prevention of delayed CINV with corticosteroids is preferred in resource-restricted settings. The expert panel also developed CINV management guidelines for anthracycline plus cyclophosphamide combination schedules, multiday cisplatin, and chemotherapy with low or minimal emetogenic potential, and its recommendations are detailed in this review. Overall, these regional guidelines provide definitive guidance for CINV management in general and resource-restricted settings. These consensus recommendations are anticipated to contribute to collaborative efforts to improve CINV management in Southeast Asia. American Society of Clinical Oncology 2016-11-09 /pmc/articles/PMC5735961/ /pubmed/29244998 http://dx.doi.org/10.1200/JGO.2016.005728 Text en © 2016 by American Society of Clinical Oncology http://creativecommons.org/licenses/by-nc-nd/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Special Articles Chan, Alexandre Abdullah, Matin M. Ishak, Wan Zamaniah B. Wan Ong-Cornel, Annielyn B. Villalon, Antonio H. Kanesvaran, Ravindran Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement |
title | Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement |
title_full | Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement |
title_fullStr | Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement |
title_full_unstemmed | Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement |
title_short | Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement |
title_sort | applicability of the national comprehensive cancer network/multinational association of supportive care in cancer guidelines for prevention and management of chemotherapy-induced nausea and vomiting in southeast asia: a consensus statement |
topic | Special Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735961/ https://www.ncbi.nlm.nih.gov/pubmed/29244998 http://dx.doi.org/10.1200/JGO.2016.005728 |
work_keys_str_mv | AT chanalexandre applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement AT abdullahmatinm applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement AT ishakwanzamaniahbwan applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement AT ongcornelannielynb applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement AT villalonantonioh applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement AT kanesvaranravindran applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement |